InsidersTradesSigma
Follow the Lineage Cell Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Lineage Cell Therapeutics, Inc. has published 38 insider filings. Market capitalisation: €284.2m. The latest transaction was reported on 12 March 2026 (Acquisition). Among the most active insiders: Culley Brian M. All data is accessible without an account.
38
Insider Decl.
n/a
Thresholds
€13m
16 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Lineage Cell Therapeutics, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$5.50.
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,414 of 29,064 companies
32.9
score / 100
Value15
Quality51
FCF yld-7.3%
Earn yld-24%
EV/EBITDA·
ROE-60%
Gross mgn99%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 March 2026
Declarations38 total
15,000 shares@ US$1.6259.0% of flowCommon SharesSEC:0001193125-26-104106:0
Canonical exit: 10 Jun 2026 (T+90)
31,250 sharesCommon SharesSEC:0001193125-26-052021:0
6,075 sharesCommon SharesSEC:0001193125-26-052020:0
1,735 sharesCommon SharesSEC:0001193125-25-327279:0
8,925 sharesCommon SharesSEC:0001193125-25-327280:0
31,249 sharesCommon SharesSEC:0000950170-25-018887:0
6,076 sharesCommon SharesSEC:0000950170-25-018897:0
7,894,737 shares@ US$0.7645.6% of flowCommon SharesSEC:0000919574-25-000555:0
Canonical exit: 27 Apr 2025 (T+90)
00Common SharesSEC:0000919574-25-000555:1
Canonical exit: 27 Apr 2025 (T+90)
15,000 shares@ US$0.5949.9% of flowCommon SharesSEC:0000950170-24-131098:0
Canonical exit: 24 Feb 2025 (T+90)
15,000 shares@ US$0.60100.0% of flowCommon SharesSEC:0000950170-24-131093:0
Canonical exit: 24 Feb 2025 (T+90)
40,000 shares@ US$0.56617.8% of flowCommon SharesSEC:0000950170-24-130592:0
Canonical exit: 20 Feb 2025 (T+90)
40,000 shares@ US$0.605.9% of flowCommon SharesSEC:0000950170-24-129972:0
Canonical exit: 19 Feb 2025 (T+90)
10,500 shares@ US$0.8950.1% of flowCommon SharesSEC:0000950170-24-098731:0
Canonical exit: 14 Nov 2024 (T+90)
10,000 shares@ US$1.052.5% of flowCommon SharesSEC:0000950170-24-064896:0
Canonical exit: 22 Aug 2024 (T+90)
31,249 sharesCommon Shares, no par valueSEC:0001493152-24-005942:0
6,076 sharesCommon Shares, no par valueSEC:0001493152-24-005944:0
96,155 shares@ US$1.04100.0% of flowCommon Shares, no par valueSEC:0001493152-24-005510:0
Canonical exit: 8 May 2024 (T+90)
6,730,770 shares@ US$1.0451.8% of flowCommon SharesSEC:0000919574-24-000757:0
Canonical exit: 6 May 2024 (T+90)
10,000 shares@ US$1.09100.0% of flowCommon Shares, no par valueSEC:0001493152-24-000154:0
Canonical exit: 28 Mar 2024 (T+90)
13,020 sharesCommon Shares, no par valueSEC:0001493152-23-004895:0
6,076 sharesCommon Shares, no par valueSEC:0001493152-23-004899:0
31,249 sharesCommon Shares, no par valueSEC:0001493152-23-004898:0
15,450 sharesCommon Shares, no par valueSEC:0001493152-22-018271:0
15,450 sharesCommon Shares, no par valueSEC:0001493152-22-009000:0
25 of 38 declarations
关于 Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. 是一家临床阶段的生物技术公司，在美国纽约证券交易所美国市场（许多投资者广义上使用的纽约证券交易所/纳斯达克）上市，其公司总部位于美国加利福尼亚州卡尔斯巴德。该公司专注于开发“现成”的同种异体细胞疗法，旨在解决具有大量未满足需求的严重医疗状况。其商业模式围绕专有的细胞工程平台AlloSCOPE以及内部开发和制造能力构建，这在细胞疗法中至关重要，因为一致性、GMP质量和可扩展生产可能与生物学本身同等重要。([lineagecell.com](https://lineagecell.com/company/)) 从历史角度看，Lineage是长期公司和战略演变的结果，最终将公司的重点缩小到再生医学和细胞疗法。随着时间的推移，该业务被重塑为一个更专业的生物技术平台，具有更清晰的临床管线和更鲜明的资本市场形象。这种重新定位对投资者很重要，因为它降低了公司的“故事风险”，并使其价值主张更直接地与少数潜在高价值项目挂钩。([investor.lineagecell.com](https://investor.lineagecell.com/node/20211/pdf?utm_source=openai)) 其管线围绕几个项目展开。主要资产是OpRegen (RG6501)，这是一种与罗氏和基因泰克合作开发的视网膜色素上皮细胞疗法，用于治疗干性年龄相关性黄斑变性，特别是地理萎缩。在神经再生领域，OPC1针对脊髓损伤，仍然是公司科学声誉的关键参考点。Lineage还在免疫肿瘤学领域开发VAC2，用于治疗听觉神经相关听力损失的ANP1，以及用于治疗光感受器功能障碍相关视力丧失的PNC1。实际上，这使得Lineage成为一个多元化的细胞疗法开发商，但仍然高度专注于专业化、高风险、高回报的适应症。([sec.gov](https://www.sec.gov/Archives/edgar/data/876343/000095017025060148/lctx_2025_ars.pdf)) 在竞争方面，Lineage被定位为利基细胞疗法专家，而非广泛的生物技术公司。其潜在优势在于同种异体、即用型产品，这些产品可能比患者特异性疗法更容易制造、储存和部署。其主要挑战是临床阶段生物技术的典型挑战：漫长的开发时间、监管不确定性、融资需求以及来自大型制药集团和资金更充足的同行在眼科、神经病学和免疫学领域寻求替代方法的竞争。从地理上看，该公司主要位于美国，总部设在加利福尼亚州卡尔斯巴德，并通过其备案文件中描述的制造和研发活动与以色列有额外的运营联系。([sec.gov](https://www.sec.gov/Archives/edgar/data/876343/000095017025060148/lctx_2025_ars.pdf)) 近期发展表明这是一个活跃的临床和运营年度。2025年，管理层强调了OpRegen的36个月临床数据更新、商业规模GMP生产的进展、OPC1的新慢性患者研究以及与William Demant Invest围绕ReSonance/ANP1治疗感音神经性听力损失的合作。公司2025-2026年的SEC Form 4文件还显示了持续的内部人交易活动，这对于关注管理层激励和内部人情绪的投资者来说可能是有用的背景信息。([investor.lineagecell.com](https://investor.lineagecell.com/node/24211/pdf))
